These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 9794194)
1. Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer. Kawasaki K; Hayashi Y; Wang Y; Suzuki S; Morita Y; Nakamura T; Narita K; Doe W; Itoh H; Kuroda Y J Gastroenterol Hepatol; 1998 Sep; 13(9):936-44. PubMed ID: 9794194 [TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Kaneko T; Konno H; Baba M; Tanaka T; Nakamura S Cancer Sci; 2003 Jan; 94(1):43-9. PubMed ID: 12708473 [TBL] [Abstract][Full Text] [Related]
3. Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues. Hong SI; Park IC; Son YS; Lee SH; Kim BG; Lee JI; Lee TW; Kook YH; Min YI; Hong WS J Korean Med Sci; 1996 Feb; 11(1):33-7. PubMed ID: 8703368 [TBL] [Abstract][Full Text] [Related]
4. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728 [TBL] [Abstract][Full Text] [Related]
5. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori. Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis. Nozaki S; Endo Y; Kawashiri S; Nakagawa K; Yamamoto E; Yonemura Y; Sasaki T Oral Oncol; 1998 Jan; 34(1):58-62. PubMed ID: 9659521 [TBL] [Abstract][Full Text] [Related]
7. Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness. Bryan L; Paugh BS; Kapitonov D; Wilczynska KM; Alvarez SM; Singh SK; Milstien S; Spiegel S; Kordula T Mol Cancer Res; 2008 Sep; 6(9):1469-77. PubMed ID: 18819934 [TBL] [Abstract][Full Text] [Related]
8. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127 [TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104 [TBL] [Abstract][Full Text] [Related]
10. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. Plebani M; Herszènyi L; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F Clin Exp Metastasis; 1997 Jul; 15(4):418-25. PubMed ID: 9219730 [TBL] [Abstract][Full Text] [Related]
11. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Hildenbrand R; Schaaf A Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473 [TBL] [Abstract][Full Text] [Related]
12. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085 [TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer. Ito H; Yonemura Y; Fujita H; Tsuchihara K; Kawamura T; Nojima N; Fujimura T; Nose H; Endo Y; Sasaki T Virchows Arch; 1996 Feb; 427(5):487-96. PubMed ID: 8624578 [TBL] [Abstract][Full Text] [Related]
14. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size. Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855 [TBL] [Abstract][Full Text] [Related]
15. Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization. Zheng MH; Fan Y; Panicker A; Smith A; Robertson T; Wysocki S; Robbins P; Papadimitriou JM; Wood DJ Am J Pathol; 1995 Dec; 147(6):1559-66. PubMed ID: 7495280 [TBL] [Abstract][Full Text] [Related]
16. Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. Zhang L; Zhao ZS; Ru GQ; Ma J World J Gastroenterol; 2006 Jul; 12(25):3970-6. PubMed ID: 16810742 [TBL] [Abstract][Full Text] [Related]
17. High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis. Thummarati P; Wijitburaphat S; Prasopthum A; Menakongka A; Sripa B; Tohtong R; Suthiphongchai T World J Gastroenterol; 2012 Jan; 18(3):244-50. PubMed ID: 22294827 [TBL] [Abstract][Full Text] [Related]
18. Plasminogen activators and inhibitors are transcribed during early macaque implantation. Feng Q; Liu K; Liu YX; Byrne S; Ockleford CD Placenta; 2001; 22(2-3):186-99. PubMed ID: 11170823 [TBL] [Abstract][Full Text] [Related]
19. Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer. Lee KH; Bae SH; Lee JL; Hyun MS; Kim SH; Song SK; Kim HS Oncology; 2004; 66(3):210-7. PubMed ID: 15218312 [TBL] [Abstract][Full Text] [Related]
20. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. Heiss MM; Babic R; Allgayer H; Gruetzner KU; Jauch KW; Loehrs U; Schildberg FW J Clin Oncol; 1995 Aug; 13(8):2084-93. PubMed ID: 7636552 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]